Live Breaking News & Updates on Sanofi aventis pakistan
Stay updated with breaking news from Sanofi aventis pakistan. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cambridge: AstraZeneca and Sanofi's Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of lower respiratory tract disease (LRTD) caused by...
According to the joint statement, Cipla will utilise its skills and solid India-wide network of distributors, institutions and market outreach programmes to expand access to these treatments for patients. Meanwhile, Sanofi India will continue to own, import, and manufacture its entire range of CNS products across plants in India and abroad.
Lantz Financial LLC trimmed its position in shares of Sanofi (NASDAQ:SNY – Free Report) by 13.5% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 4,903 shares of the company’s stock after selling 764 shares during the period. Lantz Financial […]
Belpointe Asset Management LLC raised its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 70.2% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 7,298 shares of the company’s stock after purchasing an additional 3,009 shares during the quarter. Belpointe Asset Management […]
Sanofi (NASDAQ:SNY – Free Report) – Equities research analysts at Zacks Research lowered their Q1 2024 earnings per share (EPS) estimates for shares of Sanofi in a research note issued to investors on Thursday, February 22nd. Zacks Research analyst K. Shah now expects that the company will earn $0.99 per share for the quarter, down […]
Clough Capital Partners L P purchased a new stake in Sanofi (NASDAQ:SNY – Free Report) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund purchased 274,400 shares of the company’s stock, valued at approximately $14,719,000. Sanofi accounts for about 1.6% of Clough Capital Partners L P’s portfolio, […]
Clough Capital Partners L P bought a new position in Sanofi (NASDAQ:SNY – Free Report) in the third quarter, HoldingsChannel.com reports. The firm bought 274,400 shares of the company’s stock, valued at approximately $14,719,000. Sanofi accounts for 1.6% of Clough Capital Partners L P’s investment portfolio, making the stock its 16th biggest position. Other institutional […]
Rilzabrutinib, an oral BTK inhibitor, demonstrates efficacy in reducing itch and disease activity among patients with chronic spontaneous urticaria in phase 2 dose-ranging trial at AAAAI 2024.
EPG Wealth Management LLC cut its stake in shares of Sanofi (NASDAQ:SNY – Free Report) by 8.7% during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 16,913 shares of the company’s stock after selling 1,621 shares during the period. EPG Wealth Management LLC’s holdings in […]
Clearstead Advisors LLC trimmed its stake in Sanofi (NASDAQ:SNY – Free Report) by 32.7% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 565 shares of the company’s stock after selling 275 shares during the quarter. Clearstead Advisors LLC’s holdings in […]